Request Demo
Soleno Therapeutics to Join May 2024 Investor Conferences
28 June 2024
REDWOOD CITY, Calif., May 22, 2024 — Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, has announced that its Chief Executive Officer, Dr. Anish Bhatnagar, will be participating in two significant investor conferences in June 2024.
The first event is the Jefferies Global Healthcare Conference, which is scheduled to take place on Wednesday, June 5, 2024, at 11:30 AM Eastern Time. The second event is the Goldman Sachs 45th Annual Global Healthcare Conference, set for Tuesday, June 11, 2024, at 4:00 PM Eastern Time. For those interested, live audio webcasts and replays of these events will be accessible in the Investors section of Soleno’s website.
Soleno Therapeutics is primarily engaged in the development and marketing of unique therapies aimed at treating rare medical conditions. The company’s leading product candidate is DCCR extended-release tablets, designed as a once-daily oral treatment for Prader-Willi Syndrome (PWS). This promising drug has recently completed its Phase 3 development program, paving the way for a planned New Drug Application (NDA) submission.
The first event is the Jefferies Global Healthcare Conference, which is scheduled to take place on Wednesday, June 5, 2024, at 11:30 AM Eastern Time. The second event is the Goldman Sachs 45th Annual Global Healthcare Conference, set for Tuesday, June 11, 2024, at 4:00 PM Eastern Time. For those interested, live audio webcasts and replays of these events will be accessible in the Investors section of Soleno’s website.
Soleno Therapeutics is primarily engaged in the development and marketing of unique therapies aimed at treating rare medical conditions. The company’s leading product candidate is DCCR extended-release tablets, designed as a once-daily oral treatment for Prader-Willi Syndrome (PWS). This promising drug has recently completed its Phase 3 development program, paving the way for a planned New Drug Application (NDA) submission.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.